Liver Transplant for Fatty Liver: UK Guide

Liver transplant for fatty liver disease is considered only when the condition has progressed to end-stage liver failure or severe cirrhosis. Fatty liver disease, now termed metabolic dysfunction-associated steatotic liver disease (MASLD), is increasingly a leading reason for transplant listing in the UK. However, most people with fatty liver will never need a transplant, as early and moderate disease can often be stabilised or reversed through lifestyle changes and medical management. This article explains when transplantation becomes necessary, how NHS assessment works, what lifestyle changes are required, and what alternatives exist.

Can you get a liver transplant for fatty liver disease?

Yes, a liver transplant can be performed for fatty liver disease, but only when it has progressed to end-stage liver failure or severe cirrhosis; early and moderate disease does not qualify.

Yes, a liver transplant can be performed for fatty liver disease, but only when the condition has progressed to end-stage liver failure or severe cirrhosis that cannot be managed by other means. Fatty liver disease exists on a spectrum: it begins as simple fat accumulation in liver cells (steatosis), which is generally reversible, and may progress through metabolic dysfunction-associated steatohepatitis (MASH, formerly known as NASH) to fibrosis, cirrhosis, and ultimately liver failure. Transplantation is considered only at the most advanced end of this spectrum.

In the UK, liver transplantation for metabolic dysfunction-associated steatotic liver disease (MASLD, formerly NAFLD) has become one of the leading indications for the procedure, reflecting the growing prevalence of obesity and type 2 diabetes in the population. NHS Blood and Transplant (NHSBT) publishes annual Organ Donation and Transplantation Activity Reports that track indications and listing trends, and these show that MASLD-related cirrhosis accounts for a significant and rising proportion of transplant listings.

It is important to understand that a transplant is not a treatment for early or moderate fatty liver disease. The vast majority of people with fatty liver will never require a transplant, and many can stabilise or even reverse liver damage through lifestyle changes and medical management, as outlined in NICE guidance on MASLD assessment and management (NICE NG49).^[4][5] Transplantation is reserved for those whose liver function has deteriorated to a point where survival without a new organ is unlikely. Even at that stage, severe cardiovascular disease or other significant comorbidities may mean that transplantation is not suitable for every individual, and eligibility is assessed on a case-by-case basis by the transplant team.

Bolt Pharmacy is a GPhC-registered UK online pharmacy offering online weight-management consultations, with prescriber review and pharmacist support, which may be relevant for those seeking to address the metabolic risk factors that underlie fatty liver disease.

When does fatty liver become serious enough to need a transplant?

Fatty liver disease warrants transplant assessment when it reaches decompensated cirrhosis, characterised by ascites, variceal bleeding, or hepatic encephalopathy, or when hepatocellular carcinoma develops within cirrhosis.

Fatty liver disease becomes serious enough to warrant transplant assessment when it has progressed to decompensated cirrhosis or hepatocellular carcinoma (liver cancer) arising on a background of cirrhosis. Decompensated cirrhosis is characterised by complications that the liver can no longer manage, including:

• Ascites: accumulation of fluid in the abdomen

• Variceal bleeding: rupture of enlarged blood vessels in the oesophagus or stomach

• Hepatic encephalopathy: confusion and cognitive impairment caused by toxin build-up

• Spontaneous bacterial peritonitis: infection of abdominal fluid

• Hepatorenal syndrome: kidney failure secondary to liver failure

If you or someone with you vomits blood, passes black or tarry stools, or becomes severely confused or unresponsive, call 999 or go to the nearest A&E immediately, as these may indicate variceal bleeding or severe encephalopathy requiring emergency treatment.

Clinicians use validated scoring systems to assess disease severity and transplant urgency. In the UK, NHSBT uses the UK End-Stage Liver Disease (UKELD) score to determine listing eligibility, and the NHSBT Liver Offering Scheme, which incorporates a Transplant Benefit Score, to guide organ allocation.^[3] This framework balances clinical urgency with the likely benefit of transplantation for each patient. Centres may also calculate MELD or MELD-Na scores for clinical reference, but UK listing and allocation decisions are governed by UKELD and the Liver Offering Scheme rather than MELD.

Hepatocellular carcinoma arising within cirrhosis may also qualify a patient for transplantation, provided the tumour burden falls within accepted criteria (such as the Milan criteria), as transplantation can treat both the cancer and the underlying liver disease simultaneously.^[7][8]

Not everyone with cirrhosis will reach decompensation. Compensated cirrhosis, where the liver still maintains adequate function, is managed medically and through lifestyle intervention. NICE quality standards for cirrhosis in adults (NICE QS152) recommend six-monthly ultrasound surveillance for hepatocellular carcinoma in people with cirrhosis.^[7][8] Alpha-fetoprotein (AFP) measurement may be used alongside ultrasound according to local protocols, but ultrasound is the core recommended surveillance tool. People with cirrhosis should discuss the surveillance schedule recommended for them with their specialist team.

How does the NHS liver transplant assessment process work?

Assessment begins with a specialist referral to a designated UK transplant centre, where a multidisciplinary team evaluates medical, cardiac, renal, nutritional, and psychosocial suitability over several weeks.

The NHS liver transplant assessment process begins with a referral from a hepatologist or gastroenterologist to one of the designated liver transplant centres in the UK. In England, adult liver transplantation is a nationally commissioned specialised service, commissioned by NHS England Specialised Commissioning rather than by local Integrated Care Boards (ICBs).^[9] In Scotland, Wales, and Northern Ireland, commissioning is the responsibility of the respective national health bodies. Patients should not self-refer; referrals are made by the specialist team when clinically appropriate. Information on UK transplant centres and referral pathways is available from NHSBT.

Assessment is thorough and multidisciplinary, typically taking several weeks to complete.

During assessment, the transplant team evaluates:

• Medical suitability: severity of liver disease, presence of complications, and overall fitness for major surgery

• Cardiac and respiratory function: because transplantation carries significant operative risk

• Renal function: kidney impairment is common in advanced liver disease and affects outcomes

• Nutritional status: malnutrition is prevalent and must be addressed before surgery

• Psychological and social assessment: including evaluation of support networks and capacity to adhere to post-transplant care

• Alcohol and substance use history: abstinence requirements apply where alcohol-related liver disease coexists

For patients with MASLD-related cirrhosis, the team will also assess metabolic comorbidities including obesity, type 2 diabetes, and cardiovascular disease, all of which influence surgical risk and long-term outcomes after transplantation.

If the team agrees that transplantation is appropriate, the patient is listed on the national transplant waiting list managed by NHSBT. Waiting times vary considerably depending on blood group, body size, and clinical urgency. Patients are reviewed regularly while waiting, and listing status may change if their condition improves or deteriorates. In selected cases, living donor liver transplantation may be considered; the transplant team can advise whether this is relevant for an individual patient.

What lifestyle changes are required before and after a transplant?

Before transplantation, weight optimisation, diabetes control, and nutritional rehabilitation are required; after transplantation, lifelong immunosuppressant adherence, dietary changes, and regular monitoring are essential.

Significant and sustained lifestyle changes are required both before listing for a liver transplant and throughout life after the procedure. These are not optional recommendations but clinical requirements that directly affect transplant eligibility, surgical outcomes, and long-term graft survival.

Before transplantation, the transplant team will typically require:

• Weight optimisation: severe obesity significantly increases operative risk and may preclude listing until weight is reduced. The BMI threshold varies by centre and is set individually by the transplant team rather than being a universal cut-off.

• Diabetes management: tight glycaemic control reduces infection risk and improves healing

• Cardiovascular risk reduction: smoking cessation, blood pressure control, and lipid management

• Nutritional rehabilitation: working with a dietitian to address malnutrition and muscle wasting (sarcopenia), which are common in advanced liver disease

• Physical activity: supervised exercise programmes, where tolerated, improve fitness and post-operative recovery

• Vaccination: the transplant team will review and update vaccinations before surgery, as live vaccines cannot be given after transplantation

After transplantation, lifestyle adherence becomes even more critical:

• Immunosuppressant medication must be taken exactly as prescribed, lifelong, to prevent organ rejection. Missing doses carries serious risk. Levels of medicines such as tacrolimus and ciclosporin require regular therapeutic drug monitoring.

• Drug and food interactions: grapefruit and grapefruit juice must be avoided as they affect immunosuppressant levels.^[13][14] St John's wort must not be taken as it can reduce immunosuppressant effectiveness.^[10][11] NSAIDs (such as ibuprofen) should generally be avoided. Always seek advice from the transplant team or pharmacist before starting any new prescription medicine, over-the-counter product, or herbal supplement.

• Vaccinations after transplantation: live vaccines (such as MMR, yellow fever, and live shingles vaccine) must not be given after transplantation. The transplant team will advise on which vaccines are safe and recommended.

• Infection precautions: immunosuppression increases susceptibility to infection. Contact the transplant centre promptly if you develop a fever, signs of infection, or feel unwell, as early treatment is important.

• Diet: a balanced, low-salt diet supports metabolic health and reduces the risk of MASLD recurring in the transplanted liver, which is a recognised complication

• Alcohol: complete abstinence is required for patients with any history of alcohol-related liver disease, and is strongly advised for all transplant recipients

• Weight management: MASLD can recur in the new liver, particularly if obesity and metabolic syndrome are not addressed^[28][29]

• Contraception and pregnancy planning: some immunosuppressant medicines, particularly mycophenolate, are harmful to an unborn baby. Effective contraception is essential for people of childbearing potential taking mycophenolate, and pregnancy should be planned in advance with the transplant team so that medication can be reviewed and adjusted to a pregnancy-compatible regimen before conception.

• Sun protection and skin checks: long-term immunosuppression significantly increases the risk of skin cancer.^[19][20] Use high-factor sunscreen, cover up in strong sunlight, and attend regular skin checks as advised by the transplant team.

• Regular follow-up: lifelong monitoring of liver function, kidney function, blood pressure, and metabolic parameters is essential

Patients should contact their transplant centre directly if they experience any new or concerning symptoms, and should not adjust immunosuppressant doses without medical advice. Further guidance on post-transplant care is available from the British Transplantation Society and on the NHS website.

Are there alternatives to a liver transplant for advanced fatty liver disease?

Transplantation is the only definitive treatment for end-stage liver failure, but medical management of complications, TIPS procedures, and emerging pharmacological therapies can stabilise selected patients with advanced disease.

For most people with advanced fatty liver disease, the primary alternatives to transplantation are medical management, lifestyle intervention, and treatment of complications, rather than a surgical substitute for the transplant itself. Transplantation remains the only definitive treatment for end-stage liver failure, but a proportion of patients with advanced disease can stabilise or improve sufficiently to be removed from the transplant waiting list.

Medical management of complications includes:

• Diuretics (such as spironolactone and furosemide) for ascites

• Endoscopic band ligation or beta-blockers (such as carvedilol) for varices

• Lactulose and rifaximin for hepatic encephalopathy

• Antibiotic prophylaxis for spontaneous bacterial peritonitis

If you or someone with you vomits blood, passes black or tarry stools, or becomes severely confused or unresponsive, call 999 or go to the nearest A&E immediately.

Pharmacological treatments for MASLD and MASH are an active area of development. Resmetirom (a thyroid hormone receptor beta agonist) has shown benefit in clinical trials for MASH with fibrosis.^[21][22] Its regulatory status in Europe should be confirmed with the European Medicines Agency (EMA) or a specialist, as the position may change as review processes progress. GLP-1 receptor agonists and dual GIP/GLP-1 receptor agonists are being studied for their effects on liver inflammation and fibrosis in MASLD, given their established benefits on weight and metabolic parameters; however, none of these medicines currently holds a UK marketing authorisation for the treatment of MASLD or MASH specifically, and any use in this context would be research-based or off-label. NICE guidance on specific pharmacological treatments for MASLD continues to evolve as trial data mature.

Transjugular intrahepatic portosystemic shunt (TIPS) is a radiological procedure that can relieve portal hypertension and manage refractory ascites or variceal bleeding in selected patients, though it is not suitable for everyone and carries its own risks, including worsening encephalopathy. EASL clinical practice guidelines on portal hypertension provide evidence-based criteria for TIPS use.

Hepatocellular carcinoma arising within cirrhosis may be treated with ablation, transarterial chemoembolisation (TACE), or stereotactic radiotherapy in patients who are not transplant candidates, depending on tumour stage and liver function.

Patients should discuss all available options with their hepatology team, as the most appropriate approach depends on the stage of disease, overall health, and individual circumstances. For subacute concerns such as gradually increasing abdominal swelling or mild confusion, contact your GP or call NHS 111 for advice. If you suspect a side effect from any medicine, you can report it to the MHRA via the Yellow Card scheme at yellowcard.mhra.gov.uk.

Scientific References

1. NHS Blood & Transplant: Organ Offering Scheme Algorithms.
2. Transplant benefit-based offering of deceased donor livers.
3. Effect of recipient age on prioritisation for liver transplantation (UKELD score reference).
4. Metabolic dysfunction-associated steatotic liver disease (MASLD): assessment and management (NG49).
5. Metabolic dysfunction-associated steatotic liver disease (MASLD): assessment and management – recommendations for research (NG49).
6. Metabolic Dysfunction-Associated Steatotic Liver Disease – in development (GID-NG10434).
7. Surveillance for hepatocellular carcinoma – Quality Statement 4 (QS152).
8. 6-monthly surveillance testing for hepatocellular carcinoma (QS65).
9. Non-alcoholic fatty liver disease (NAFLD).
10. Impact of St John's wort treatment on the pharmacokinetics of tacrolimus.
11. St John's wort – Interactions.
12. St John's wort: a hidden risk for transplant patients.
13. Delayed effect of grapefruit juice on pharmacokinetics and pharmacodynamics of tacrolimus.
14. Severe rise in tacrolimus levels following blood orange and grapefruit juice intake in a kidney transplant recipient.
15. Assessment of the Intestinal CYP3A Contribution to Drug Interactions with Extended-Release Tacrolimus (LCPT) Using Grapefruit Juice.
16. EMA recommends additional measures to prevent use of mycophenolate in pregnancy.
17. Mycophenolate mofetil/mycophenolic acid: updated contraception advice for male patients.
18. Patient Guide – Mycophenolate: Risks of Miscarriage and Birth Defects.
19. Missed opportunities for prevention: deficits in skin cancer and sun protection knowledge before solid organ transplantation.
20. Increased Risk for Ocular Surface Neoplasia in Recipients of Solid Organ Transplant.
21. A Scoping Review of Resmetirom First Year in Real-World Practice.
22. First treatment against liver scarring caused by a type of fatty liver disease (Rezdiffra/resmetirom).
23. Rezdiffra (resmetirom) – European Medicines Agency EPAR.
24. Resmetirom (Rezdiffra) authorised to treat metabolic dysfunction-associated steatohepatitis (MASH) in adults.
25. Phase 3 Trial of Resmetirom Versus Placebo in MASH – reanalysis of fibrosis stage 2–3 subset. Alimentary Pharmacology & Therapeutics.
26. Semaglutide (Wegovy) approved to treat form of liver disease.
27. Semaglutide for treating moderate to advanced liver fibrosis caused by MASH – in development (GID-TA11477).
28. Metabolic comorbidities and post-transplant outcomes in MASLD: a cohort study from a Brazilian tertiary centre. Archives of Endocrinology and Metabolism.
29. The Outcomes of Liver Transplantation in Severe Metabolic Dysfunction-Associated Steatotic Liver Disease Patients. Biomedicines.
30. EASL Clinical Practice Guidelines on TIPS.
31. Navigating TIPS in the era of ageing and metabolic comorbidity: a contemporary narrative review. Gastroenterology Report.
32. Effect of Transjugular Intrahepatic Portosystemic Shunt on Intestinal Flora in Liver Cirrhosis: A Systematic Review. Euroasian Journal of Hepato-Gastroenterology.

Frequently Asked Questions